

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

The Isoquinoline Alkaloid Berberine Inhibits Human Cytomegalovirus Replication by Interfering with the Viral Immediate Early-2 (IE2) Protein Transactivating Activity

Anna Luganini^{1,3}, Beatrice Mercorelli^{2,3}, Lorenzo Messa², Giorgio Palù², Giorgio Gribaudo^{1,4*},
Arianna Loregian^{2,4*}

¹Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy.

²Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.

³Co-first author.

⁴Co-senior author.

*Correspondence: giorgio.gribaudo@unito.it; arianna.loregian@unipd.it

Abbreviations: BBR, berberine; IE2, Immediate-Early 2; IE3, Immediate-Early 3; GCV, ganciclovir; CDV, cidofovir; FOS, foscarnet; NTZ, nitazoxanide.

60
61
62 **Abstract**
63

64 The identification and validation of new small molecules able to inhibit the replication of
65 human cytomegalovirus (HCMV) remains a priority to develop alternatives to the currently used
66 DNA polymerase inhibitors, which are often burdened by long-term toxicity and emergence of
67 cross-resistance. To contribute to this advancement, here we report on the characterization of the
68 mechanism of action of a bioactive plant-derived alkaloid, berberine (BBR), selected in a previous
69 drug repurposing screen expressly devised to identify early inhibitors of HCMV replication. Low
70 micromolar concentrations of BBR were confirmed to suppress the replication of different HCMV
71 strains, including clinical isolates and strains resistant to approved DNA polymerase inhibitors.
72 Analysis of the HCMV replication cycle in infected cells treated with BBR then revealed that the
73 bioactive compound compromised the progression of virus cycle at a stage prior to viral DNA
74 replication and Early (E) genes expression, but after Immediate-Early (IE) proteins expression.
75 Mechanistic studies in fact highlighted that BBR interferes with the transactivating functions of the
76 viral IE2 protein, thus impairing efficient E gene expression and the progression of HCMV
77 replication cycle. Finally, the mechanism of the antiviral activity of BBR appears to be conserved
78 among different CMVs, since BBR suppressed murine CMV (MCMV) replication and inhibited the
79 transactivation of the prototypic MCMV *E1* gene by the IE3 protein, the murine homolog of IE2.
80 Together, these observations warrant for further experimentation to obtain proof of concept that
81 BBR could represent an attractive candidate for alternative anti-HCMV therapeutic strategies.
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107

108 **Keywords:** Berberine chloride; Human Cytomegalovirus; Murine Cytomegalovirus; IE2; IE3;
109 Promoter transactivation.
110
111
112
113
114
115
116
117
118

1. Introduction

Human cytomegalovirus (HCMV) represents one of the most important opportunistic human pathogens. It belongs to the *Beta-herpesvirinae* subfamily and rarely causes symptomatic clinical manifestations in immunocompetent individuals (Griffiths et al., 2015; Lukanini et al., 2016; Britt & Prichard, 2018). However, HCMV induces severe morbidity and mortality in the immunocompromised population following reactivation or primary infection, leading to gastrointestinal diseases, pneumonia, retinitis, and other organs' infections (Griffiths et al., 2015; Lukanini et al., 2016). Moreover, HCMV is also the viral leading cause of congenital defects in newborn children, causing deafness and other neurological disorders in approximately 0.1% cases of congenital infections (Britt, 2018). Understanding the molecular mechanisms of HCMV replication and identifying essential viral and host factors involved in productive infection is mandatory for the development of new effective antiviral agents and therapeutic strategies that could fill the gap left by the currently approved anti-HCMV therapies. In fact, the drugs available for the treatment of HCMV infections suffer from several drawbacks, including long-term toxicity and poor bioavailability (Meesing and Razonable, 2018). In addition, since the anti-HCMV drugs all share a common target (i.e., the viral DNA polymerase), the possibility may occur that drug-resistant viruses selected during long-term therapy are also cross-resistant to all the available drugs, leaving the patient bereft of therapeutic options (Haidar and Singh, 2017; Razonable, 2018). A step forward was the very recent approval of letermovir, a viral terminase inhibitor, albeit only as a prophylactic agent for preventing HCMV disease in patients undergoing hematopoietic stem cells transplantation (Bray et al., 2018; Marty et al., 2017). For all these reasons, there is an evident medical need for the development of new anti-HCMV drugs with a favorable pharmacological profile and directed against different viral targets.

The multifunctional and essential viral Immediate-Early 2 (IE2) protein is thought one of the most promising new targets for anti-HCMV drug discovery, and over time targeting IE2 expression

178
179
180 or activity has been proven to represent an effective antiviral strategy ((Scholz et al., 2001;
181
182 Mercorelli et al., 2014a). Indeed, ISIS 2922 (fomivirsen), an antisense phosphorothioate
183
184 oligonucleotide complementary to the mRNA encoding IE2 and thus able to prevent IE2 protein
185
186 expression, is a drug approved for treatment of HCMV diseases, although infrequently used
187
188 compared to ganciclovir (GCV) (Britt & Prichard, 2018). More recently, several small molecules,
189
190 including already approved drugs, have been reported to interfere with the expression or activity of
191
192 IE2 (Mercorelli et al., 2014b; Gardner et al., 2015; Mercorelli et al., 2016; Beelontally et al., 2017;
193
194 Mercorelli et al., 2018a). In detail, we focused on the gene transactivating activity of IE2 (Stinski &
195
196 Petrik, 2008) as a HCMV-specific target for a drug-repurposing cell-based screening of a library of
197
198 both approved drugs and natural bioactive compounds (Mercorelli et al., 2016). Among the 38
199
200 identified hits, the anti-parasitic drug nitazoxanide (NTZ) was observed to inhibit HCMV
201
202 replication, as well as viral Early (E) and Late (L) gene expression and DNA synthesis. Mechanistic
203
204 studies then revealed that NTZ hindered the IE2-dependent transactivation of essential viral E genes
205
206 (Mercorelli et al., 2016). NTZ represents therefore the prototype of a novel class of anti-HCMV
207
208 agents that can act by interfering with the transactivating activity of IE2. The natural compound
209
210 berberine hydrochloride (BBR) was another of the molecules selected by the screening that showed
211
212 a potent inhibitory activity on HCMV replication at low-micromolar concentrations (Mercorelli et
213
214 al., 2016).

215
216
217
218 BBR is an isoquinoline alkaloid that can be isolated from different plants belonging to the
219
220 *Berberis* genus and is a traditional component of Chinese and Ayurvedic medicine used since
221
222 millenniums for its antimicrobial and antiparasitic effects (Imenshahidi and Hosseinzadeh, 2016;
223
224 Kumar et al., 2015). Currently, BBR is under preclinical and clinical investigation for its broad-
225
226 spectrum pharmacological properties, including anti-cancer, anti-diabetes, and anti-hypertensive
227
228 activities (Imenshahidi and Hosseinzadeh, 2016; Kumar et al., 2015). An inhibitory activity of BBR
229
230 have been already reported against different viruses, such as herpesviruses (herpes simplex virus
231
232 and HCMV) (Song et al., 2014; Hayashi et al., 2007), influenza virus (Cecil et al., 2011),
233
234
235
236

237
238
239 respiratory syncytial virus (RSV) (Shin et al., 2015), alphavirus (Varghese et al., 2016a; Varghese
240 et al., 2016b), enterovirus (Wang et al., 2017), and flavivirus (Robinson et al., 2018). Moreover,
241
242 BBR is used as a common dietary supplement all over the world and thus its repurposing potential
243
244 is high.
245
246

247
248 However, in the case of HCMV, the mechanism of the antiviral activity of BBR has not
249
250 been investigated. Here, we report the characterization of the mechanism of action of BBR against
251
252 both HCMV and the murine cytomegalovirus (MCMV) and provide strong evidence that BBR
253
254 targets the activity of the HCMV transcription factor IE2, as well as of its murine homolog IE3.
255
256

257 258 **2. Materials & Methods**

259 260 *2.1 Compounds*

261
262 Berberine chloride (BBR), nitazoxanide (NTZ), foscarnet (FOS), and ganciclovir (GCV)
263
264 were purchased from Sigma-Aldrich. Cidofovir (CDV) was from Gilead Sciences. Fomivirsen (ISIS
265
266 2922) was synthesized by Metabion International AG. The anti-HCMV 6-aminoquinolone
267
268 compound WC5 was previously described (Mercorelli et al., 2009).
269
270

271 272 *2.2 Cells and viruses*

273
274 Human Foreskin Fibroblasts (HFF), low-passage number human embryonic lung fibroblasts
275
276 (HELFL), U373-MG, and NIH 3T3 cells were cultured in Dulbecco modified Eagle's medium
277
278 (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Euroclone), 2 mM
279
280 glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 µg/ml streptomycin sulfate (P/S,
281
282 both from Euroclone) at 37°C in a humidified atmosphere supplemented with 5% CO₂. Quiescent
283
284 HELFs were obtained by culturing the subconfluent cultures for 48 h in DMEM supplemented with
285
286 0.5% serum (low-serum medium).
287
288

289
290 HCMV laboratory strain AD169 was purchased from American Type Culture Collection
291
292 (ATCC; VR-538). HCMV TB40-UL32-EGFP (kindly provided by C. Sinzger, University of Ulm,
293
294
295

296
297
298 Germany) was previously described (Sampaio et al., 2005). HCMV VR1814 (kindly provided by G.
299
300 Gerna, IRCCS Policlinico San Matteo, Pavia, Italy) was recovered from a cervical swab from a
301
302 pregnant woman (Revello et al., 2001). HCMV 388438U, a clinical isolate of HCMV, was collected
303
304 from a urine sample at the Microbiology and Virology Unit of Padua University Hospital (Italy) and
305
306 was at passage 4 after primary isolation. HCMV strains resistant to antiviral drugs were obtained
307
308 from the NIH AIDS Research and Reference Reagent Program (Rockville, MD) and were
309
310 previously described (Mercorelli et al., 2009). Murine cytomegalovirus (MCMV) strain Smith was
311
312 purchased from the ATCC (ATCC VR-194). Recombinant adenoviral vectors expressing HCMV
313
314 IE2 or *E. coli* β -galactosidase (LacZ) were previously described (Mercorelli et al., 2014).
315
316
317
318
319

320 *2.3 Plaque reduction assays*

321
322 For plaque reduction assays (PRA) with HCMV and MCMV, HFF and NIH 3T3 cells,
323
324 respectively, were seeded in 24-well plates. The next day, cell monolayers were infected at 37°C
325
326 with 100 Plaque Forming Units (PFU) per well of the different viral strains. At 2 h post-infection
327
328 (p.i.), viral inocula were removed, cells were washed, and media containing increasing
329
330 concentrations of each compound, 5% FBS, and 0.6% methylcellulose were added. All compound
331
332 concentrations were tested at least in duplicate. After 10 days for HCMV and 6 days for MCMV,
333
334 cell monolayers were fixed, stained with crystal violet, and viral plaques were microscopically
335
336 counted.
337
338
339
340

341 *2.4 Cytotoxicity assays*

342
343 The cytotoxicity of BBR and reference compounds were determined by the 3-(4,5-
344
345 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) method, as
346
347 described previously (Loregian and Coen, 2006).
348
349
350

351 *2.5 Quantitative Real-Time PCR*

355
356
357 To analyze the effects of BBR on HCMV DNA synthesis, HFFs were seeded at a density of
358
359 1.5×10^5 per well in 24-well plates. The next day, cell monolayers were infected with HCMV
360
361 AD169 at a multiplicity of infection (MOI) of 0.1 PFU/cell and, following virus adsorption (2 h at
362
363 37°C), were incubated with 50 μ M BBR or 25 μ M GCV as a control. At different times p.i., cells
364
365 were collected and total DNA was extracted. The levels of viral DNA were then determined by
366
367 quantitative Real-time PCR (qPCR) and normalized to the cellular *β -globin* gene copies as
368
369 previously described (Loregian et al., 2010). The oligonucleotide sequences used for the qPCR
370
371 experiments were previously reported (Mercorelli et al., 2016).
372
373
374
375

376 *2.6 Immunoblotting*

377

378 Sub-confluent HFF cells cultured in 6-well plates were infected with HCMV AD169 at an
379
380 MOI of 0.5 PFU/cell. Following virus adsorption, cells were treated with 50 μ M BBR, 30 μ M NTZ,
381
382 or with DMSO (0.1% v/v) as a control. Whole-cell protein extracts were prepared at different times
383
384 p.i. as previously described (Cavaletto et al., 2015), fractionated through 8% SDS-PAGE, and then
385
386 transferred to PVDF membranes (BioRad). After blocking with 5% nonfat dry milk in TBS-Tween
387
388 0.05%, membranes were incubated overnight at 4°C with the following mAbs: anti-IEA (IE1 and
389
390 IE2) (1:2000, clone CH160, Virusys), anti-UL44 (1:2000, clone CH16, Virusys), anti-UL99
391
392 (1:2000, clone H19, Virusys), and anti-tubulin (1:2000, clone TUB 2.1, Sigma) as a control for
393
394 protein loading. Immunocomplexes were then detected with a goat anti-mouse Ig Ab conjugated to
395
396 horseradish peroxidase (Life Technologies) and visualized by enhanced chemiluminescence
397
398 (Western Blotting Luminol Reagent, Santa Cruz).
399
400
401
402
403

404 *2.7 Plasmids*

405

406 The pUL54-luciferase indicator plasmids pUL54-0.4, bearing the entire HCMV *UL54*
407
408 promoter, and pUL54-0.15, containing *UL54* promoter sequence from -150 to +15 relative to the
409
410 transcription start site, were previously described (Gariano et al., 2012). pRL-TK and pSV-Rluc
411
412
413

414
415
416 vectors expressing *Renilla* luciferase were purchased from Promega. The indicator plasmids pE(-
417 207)Luc and pME(-207)Luc containing the firefly luciferase reporter gene under control of wt and
418 207)Luc and pME(-207)Luc containing the firefly luciferase reporter gene under control of wt and
419 mutated cellular cyclin E promoter, respectively, were kindly provided by E.A. Thompson (Mayo
420 Clinic Florida, FL) and were previously described (Bresnahan et al., 1998). Generation of the
421 pGL3-MIEP-crs wt plasmid expressing firefly luciferase under the control of HCMV Major
422 Immediate Early promoter was previously described (Mercorelli et al., 2014). The pGL4.10-luc2-
423 LTR construct expressing the luciferase indicator gene under the control of HIV-1 LTR was
424 previously described (Perrone et al., 2013). pRPneo/SL3/Tat expressing HIV-1 Tat protein was
425 previously described (Gibellini et al., 1995). The firefly luciferase indicator construct phTS-
426 243/+30 contains a portion of the promoter of the human thymidylate synthase gene (TS) (-243 and
427 +30 relative to the transcription start codon) cloned into pGL3-basic vector (Promega) (Gribaudo et
428 al., 2002). The pSGIE72 and pSGIE86 constructs, expressing the HCMV IE1-72 kDa or IE2-86
429 kDa proteins respectively, were generated as described previously (Klucher et al., 1993). The empty
430 pSG5 expression vector was purchased from Agilent Technologies. The pGL3-E1 vector, harboring
431 the MCMV early gene *E1* promoter responsive to IE3 protein (the MCMV homolog of HCMV
432 IE2), was generated as previously reported (Mercorelli et al., 2014). The pIE3 plasmid for the
433 expression of IE3 was described previously (Messerle et al., 1992). pBSK plasmid was purchased
434 from Agilent Technologies.

454 2.9 Cell transfection and adenoviral transduction

455
456
457 All transient transfection experiments in HELF cells were performed using Lipofectamine
458 3000 (Life Technologies). For transfection/transduction experiments, HELF grown on 24-well
459 plates were transfected with the luciferase reporter plasmid driven by either the UL54-0.4 or UL54-
460 0.15 gene promoter, and the pRL-TK plasmid expressing *Renilla* luciferase to normalize variations
461 in transfection efficiency (Mercorelli et al., 2016). At 24 h post-transfection, cells were transduced
462 with AdvIE2, or AdvLacZ as a control, at an MOI of 20 PFU/cell for 2 h at 37°C, and then treated
463
464
465
466
467
468
469
470
471
472

473
474
475 with 50 μ M BBR, 30 μ M NTZ, 5 μ M ISIS 2922, or 0.1% DMSO (v/v). At 48 h post-transduction,
476
477 cell extracts were prepared and firefly and *Renilla* luciferase activities were measured.
478

479
480 To evaluate the effect of BBR on the TS gene promoter activity, HELF cells were co-
481
482 transfected with phTS-243/+30, pSGIE72, or the empty pSG5 vector, along with pRL-TK plasmid.
483
484 At 18 h post-transfection, cells were washed with warm medium and incubated in low-serum
485
486 medium (0.2% FBS) containing 50 μ M BBR, 30 μ M NTZ, or 0.1% DMSO (v/v) for 48 h before
487
488 measuring firefly and *Renilla* luciferases activities (Gribaudo et al., 2002; Mercorelli et al., 2018).
489
490 Transient transfections in U373-MG cells were performed using calcium phosphate precipitation
491
492 method (CellPect Transfection Kit, GE Healthcare). Briefly, U373-MG were seeded in 24-well
493
494 plates and the next day were transiently co-transfected with 0.5 μ g of plasmids containing different
495
496 promoters (*cyclin E* both wt and mutated, HCMV MIEP, and HIV-1 LTR) and, where indicated,
497
498 pSGIE86 or Tat-expressing plasmids in 1:3 ratio, along with 0.25 μ g of pSV-Rluc plasmid as a
499
500 control for transfection efficiency. Total DNA amount was equalized with pSG5 empty vector.
501
502 After incubation for 4 h at 37°C, the transfection mixtures were removed and medium containing
503
504 either BBR or DMSO (0.1%) as a control was added to the cells. To investigate whether BBR could
505
506 affect the transactivation of MCMV *E1* gene promoter by the IE3 protein, NIH 3T3 cells grown on
507
508 24-well plates were co-transfected using Lipofectamine 3000 with 0.75 μ g of luciferase reporter
509
510 plasmid pGL3-E1 and, where indicated, with 1.5 μ g of pIE3 plasmid and with 0.15 μ g pRL-TK
511
512 plasmid. In control transfections, the total amount of DNA was equalized with pBSK. After 3 h at
513
514 37°C, transfected cells were treated with 50 μ M BBR, or 50 μ M WC5 as a positive control, or 0.1%
515
516 DMSO (v/v) as a negative control. At 48 h post-transfection, cells were harvested for the
517
518 measurement of firefly and *Renilla* luciferase activities. For all transfection experiments, firefly and
519
520 *Renilla* luciferase activities were measured using the Dual-Luciferase reporter assay system kit
521
522 (Promega).
523
524
525
526
527

528 2.10 Statistical analysis

529
530
531

532
533
534 All statistical analyses were performed using GraphPad Prism version 5.00 for Windows
535
536 (www.graphpad.com; GraphPad Software, San Diego, CA).
537

538 539 540 541 **3. Results**

542 543 *3.1 Berberine exerts broad-spectrum anti-HCMV activity*

544
545 In a drug repurposing screening specifically designed to identify inhibitors of the HCMV
546 transcription factor IE2, we identified the bioactive plant-derived BBR as a hit compound
547
548 (Mercorelli et al., 2016). The observation of the anti-HCMV activity of BBR in our experimental
549 setting prompted us to characterize deeper its mechanism of action. To this end, we first confirmed
550
551 the anti-HCMV activity and cytotoxicity of BBR in HFF cells by PRAs and MTT assays,
552
553 respectively (Table 1). According to our previous observations (Mercorelli et al., 2016), BBR
554 specifically inhibited HCMV AD169 replication in a dose-dependent manner (Fig. 1) with an
555
556 Effective Concentration (EC₅₀) of 2.65 μM. This value was very similar to that measured for GCV
557
558 in our experimental conditions (Table 1). The Cytotoxic Concentration (CC₅₀) determined by MTT
559
560 assays was 390 μM, thus resulting in a favorable Selectivity Index (SI) of 147 (Table 1). In this
561
562 regard, a similar SI value was previously observed for BBR in MRC5 cells (Hayashi et al., 2007).
563
564 To further characterize the anti-HCMV activity of BBR, we performed PRAs with several HCMV
565
566 strains, including different low-passage clinical isolates (TB40-UL32-EGFP, VR1814, and
567
568 388438U). Results reported in Table 2 indicated that the anti-HCMV activity of BBR is not
569
570 dependent on the viral strain used for the studies, since the EC₅₀ values obtained with different
571
572 HCMV strains were all comparable.
573
574
575
576
577
578
579
580

581 *3.2 Activity of BBR against drug-resistant HCMV strains*

582
583 Next, we evaluated the activity of BBR against HCMV strains resistant to the available viral
584
585 DNA polymerase inhibitors, as the emergence of drug resistance is an increasing cause of transplant
586
587 failure associated with HCMV infections, in particular after prolonged antiviral therapy (Razonable,
588
589
590

591
592
593 2018). BBR fully inhibited the replication of viruses with mutations in *UL54* gene conferring cross-
594 resistance to GCV and CDV and to FOS and acyclovir (strains GDG^rP53 and PFA^rD100,
595 respectively, Table 3). These results suggested that BBR may have a mechanism of action that
596 differs from that of the currently available anti-HCMV drugs that target the viral DNA polymerase.
597
598
599

600 601 602 603 604 *3.3 BBR inhibits HCMV DNA replication*

605
606 To investigate the effect of BBR on the replication of HCMV genome, we performed a
607 quantitative analysis of viral DNA production at different times p.i.. As depicted in Fig. 2, a
608 progressive increase of viral DNA levels was detected by qPCR in a time-dependent manner up to
609 120 h p.i. in untreated infected cells. In contrast, already at 72 h p.i. (i.e., after a completed cycle of
610 replication), BBR, like the specific HCMV DNA polymerase inhibitor GCV, significantly inhibited
611 the replication of viral genome. The inhibitory activity of BBR was confirmed later at 96 and 120 h
612 p.i. (Fig. 2). Thus, most likely BBR affects a stage of the HCMV replication cycle that is located
613 prior to the onset of viral DNA replication and this interference resulted in a significant impairment
614 of viral DNA synthesis.
615
616
617
618
619
620
621
622
623
624
625
626
627
628

629 630 631 632 633 *3.4 BBR interferes with the HCMV replication cycle after the IE phase*

634
635 To determine whether the observed inhibition of HCMV DNA synthesis (Fig. 2) was a
636 consequence of a BBR-mediated effect on viral IE and/or E gene expression that foreruns viral
637 genome replication, HFFs were infected with HCMV AD169 and treated with BBR for different
638 times p.i. Then, total protein cell extracts were assayed by immunoblotting for the content of
639 representative Immediate-Early (IE1 and IE2), Early (UL44), and Late (UL99) viral proteins
640 (Figure 3). For each time p.i. analyzed, control samples were: (i) extracts prepared from AD169-
641 infected cells treated with the appropriate DMSO amount, and (ii) AD169-infected cells treated
642 with NTZ, as a positive control for inhibition of the expression of Early and Late HCMV proteins
643
644
645
646
647
648
649

650
651
652 (Mercorelli et al., 2016). Figure 3 shows that BBR did not seemingly affect IE1 and IE2 protein
653 accumulation at each time analyzed. In contrast, compared to the untreated cells, BBR determined a
654 clear reduction in UL44 and UL99 levels, although less markedly than NTZ, which was used as a
655 positive control. Taken together, these results indicated that BBR affects HCMV replication cycle
656 after the expression of IE proteins and, together with those reported in Fig. 2, suggested that BBR
657 likely interferes with a molecular event involved in the expression of HCMV E genes.
658
659
660
661
662
663
664
665
666

667 *3.5 BBR inhibits the IE2-dependent transactivation of both viral and cellular promoters*

668

669 To investigate whether BBR might affect the transactivation of E genes of HCMV,
670 luciferase reporter plasmids containing full-length or a minimal *UL54* gene promoter were
671 transfected in HELFs. The *UL54* promoter is a prototypic HCMV E gene promoter that is
672 transactivated by IE2, thus its activation marks out the E phase of HCMV replicative cycle (Stinski
673 & Petrik, 2008). Two luciferase reporter plasmids containing different segments of the *UL54* gene
674 5'-flanking region were used: the UL54-0.4 construct includes the full-length gene promoter, while
675 the UL54-0.15 plasmid carries a segment of 150 bp upstream from the transcription start site
676 (Gariano et al., 2012). This shorter portion of the *UL54* 5'-flanking region mediates the IE2-
677 dependent transactivation of the *UL54* gene at a level comparable to that of the full-length
678 promoter. Furthermore, it includes an 8-bp inverted repeat element 1 (IR-1, located between -55 and
679 -48 nt relative to the transcription start site) which has been shown to be required for both HCMV-
680 and IE2-mediated transactivation (Kerry et al. 1996). Thus, to identify the minimal portion of the
681 *UL54* gene promoter sufficient to mediate the sensitivity to BBR, the UL54-0.15 construct was also
682 included in transfection-transduction experiments. At 24 h post-transfection, HELFs were
683 transduced with the adenoviral vectors AdVIE2 or AdvLacZ as a negative control of transcriptional
684 activation, and, after additional 2h, treated with BBR, ISIS 2922, or NTZ. The latter two
685 compounds were employed as positive controls for inhibition of the IE2-dependent *UL54* gene
686 promoter transactivation (Mercorelli et al., 2016). As shown in Fig. 4A, ectopic expression of IE2
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708

709 significantly increased the transcriptional activity of both *UL54* reporter constructs compared to
710 cells expressing LacZ. As expected, both NTZ and ISIS 2922, both used as a positive control,
711 inhibited the IE2-dependent transactivation of the *UL54*-0.4 promoter by 87% and 95%,
712 respectively (Mercorelli et al., 2016). Interestingly, also treatment with BBR decreased the
713 transcriptional activity of the full-length *UL54*-0.4 promoter by 77% and that of the minimal
714 promoter *UL54*-0.15 by about 65% (Fig. 4A). These data indicated the ability of at BBR to interfere
715 with the IE2-dependent transactivation of the promoter of an essential viral E gene, and that a
716 segment of 150 bp upstream from the *UL54* transcription initiation site is sufficient to mediate the
717 inhibitory activity of BBR.
718

719 The above observation then prompted the investigation on the effect of BBR on the activation of
720 other gene promoters that can be activated by IE2. Cellular cyclin E (*CycE*) gene expression is up-
721 regulated upon HCMV infection in quiescent cells to promote G0/G1 transition and its
722 transcriptional activation can be directly stimulated by IE2 (Bresnahan et al., 1998). To assess the
723 effect of BBR on the IE2-mediated transactivation of *CycE* gene promoter, we co-transfected
724 permissive U373-MG cells with a construct expressing IE2 together with reporter constructs
725 containing either a portion of wt *CycE* promoter (pCycE) or a mutated version wherein the binding
726 sites for the cellular transcription factor E2F at -16 and +7 have been mutated (mpCycE). As shown
727 in Fig. 4B, BBR efficiently inhibited the IE2-dependent transactivation of the pCycE. Similar
728 results were obtained in cells transfected with mpCycE construct, thus indicating that disruption of
729 E2F binding sites of the *CycE* gene promoter did not affect the inhibitory activity exerted by BBR
730 (Fig. 4C).
731

732 Taken together, these results suggest that BBR affects the transactivation of both viral and
733 cellular promoters, which are known to depend on IE2 for their activation.
734

735 *3.6 BBR is not a general inhibitor of viral and cellular transcription*

736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767

768
769
770 To investigate whether the inhibitory effect of BBR was specific for IE2 and not due to a
771 general inhibition of transcription, the activities of two other viral promoters, i.e., the MIEP of
772 HCMV and the LTR of HIV-1, which contain multiple binding sites for general cellular
773 transcription factors, were examined for their sensitivity to BBR. Although an inhibitory activity of
774 BBR on the basal activity of both viral promoters was observed (Fig. 5A), it was not as solid or
775 dose responsive as that measured on the IE2-dependent transactivation of both *UL54* and *CycE* gene
776 promoters (Fig. 4). Moreover, since the HIV-1 LTR can be specifically transactivated by the virus-
777 encoded Tat transcription factor (Ne et al., 2018), we also investigated the effect of BBR on the Tat-
778 mediated transactivation of LTR. As shown in Figure 5B, BBR did not affect the Tat-mediated
779 transactivation of HIV-1 LTR. These results thus suggest that most likely BBR is not a general
780 inhibitor of transcription.
781
782

793 Then, to further strengthening the specificity of IE2 inhibition by BBR, we evaluated its
794 effect on the activity of the other major HCMV-encoded IE transcription factor, IE1. IE1 and IE2
795 proteins originate from a single precursor RNA through alternative splicing, therefore IE1 shares
796 the same first three exons (85 aa) with IE2 (Stinski and Petrik, 2008). We previously reported that
797 IE1 transactivates the human thymidylate synthase (TS) gene promoter to stimulate cellular TS
798 activity that is required for HCMV DNA replication in quiescent cells (Gribaudo et al., 2002).
799 Based on this premise, we investigated the effects of BBR on the IE1-dependent transactivation of
800 the human *TS* gene promoter. To this end, HELFs cells were co-transfected with pHTS-243/+30 and
801 an IE1 expression vector. As reported in Fig. 5C, IE1-dependent transactivation of the human *TS*
802 promoter was not affected by the treatment with BBR. NTZ, included as a control of a specific
803 inhibitor of the IE2-mediated transactivation, did not affect the IE1-mediated activation of cellular
804 *TS* gene promoter as previously observed (Mercorelli et al., 2016).
805
806
807
808
809
810
811
812
813
814
815
816
817
818

819 Altogether, these results indicate that the observed BBR-mediated inhibition of IE2-
820 dependent transactivating activity is not due to a general inhibitory effect on transcription.
821 Moreover, together with those reported in Fig. 4, they sustain the hypothesis that the overall
822
823
824
825
826

827
828
829 inhibitory activity of BBR against HCMV likely stems from its ability to interfere with the
830 expression of critical E genes required for viral DNA synthesis and progression of HCMV
831 replication cycle.
832
833
834
835
836
837

838 *3.7 BBR prevents murine CMV replication and inhibits the IE3-dependent transactivation of the* 839 *Early E1 gene promoter*

840
841
842 Finally, we evaluated the activity of BBR also against murine CMV (MCMV). To this end,
843 PRAs were performed in NIH 3T3 fibroblasts infected with the Smith strain of MCMV. As reported
844 in Table 4, BBR fully retained antiviral activity against MCMV and the measured EC₅₀ values were
845 comparable to those obtained for the HCMV strains (Tables 1 to 3). Moreover, BBR did not show
846 any significant cytotoxicity in uninfected cells, confirming that the inhibition of the virus replication
847 was due to a specific antiviral effect.
848
849
850
851
852
853

854
855 Having established that BBR is also active against MCMV, we wondered whether the
856 mechanism of action of BBR against MCMV may be the same observed for the human virus. To
857 this end, NIH 3T3 cells were transfected with an indicator plasmid containing the luciferase gene
858 driven by the prototypic MCMV Early *E1* gene promoter (pGL3-E1), together with an IE3-
859 expressing vector (pIE3). The MCMV IE3 protein is the structural and functional homolog of
860 HCMV IE2 (Messerle et al., 1992). Transfected NIH 3T3 cells were then treated with BBR or
861 WC5, used as a control for inhibition of MCMV E1 promoter (Mercorelli et al., 2014). As shown in
862 Fig. 6, the expression of IE3 increased the activity of the *E1* gene promoter of more than 50-fold.
863 Treatment with BBR reduced the IE3-dependent transactivation of the *E1* gene promoter by 60%
864 compared to that of DMSO-treated cells. As expected, WC5 reduced the luciferase activity by 71%
865 (Mercorelli et al., 2014). These results thus indicated that the mechanism of action of BBR against
866 HCMV is conserved also against MCMV.
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882

883 **4. Discussion**

884
885

886
887
888
889 The identification and validation of new antiviral molecules to prevent or limit HCMV
890 replication remains a priority for the clinical management of HCMV infections. Since IE2 plays a
891 critical role in the progression of HCMV replication, as well in virus pathogenesis and reactivation
892 from latency (Scholz et al., 2001; Stinski and Petrik, 2008), we and others have addressed the
893 identification and characterization of small molecules that could block IE2 synthesis or activities
894 (Mercorelli et al., 2014a, b; Gardner et al., 2015; Mercorelli et al., 2016; Beelontally et al., 2017;
895 Mercorelli et al., 2018a). In a drug repurposing screen devised to select early inhibitors of HCMV
896 replication, we previously identified 38 different molecules active in the inhibition of HCMV E
897 gene expression (Mercorelli et al., 2016). To date, some of them have been confirmed to selectively
898 inhibit the IE2-mediated transactivation of essential viral E genes and hence HCMV replication
899 (Mercorelli et al., 2016; Mercorelli et al., 2018a). Here, we add another piece of knowledge about
900 this novel class of IE2 inhibitors by reporting the characterization of the mechanism of action of
901 BBR, one of the compounds selected in the drug repurposing screen for its anti-HCMV activity.
902
903
904
905
906
907
908
909
910
911
912
913
914
915

916 BBR is an isoquinoline alkaloid present in several medicinal plants including *Berberis*
917 *vulgaris*, *Coptis chinensis*, *Hydrastis canadensis*, and *Rhizoma coptidis*, and over the past years
918 several biological effects of BBR have been reported, including antimicrobial activities against
919 bacteria, fungi, and viruses (Imenshahidi and Hosseinzadeh, 2016; Kumar et al., 2015). In this
920 regard, an inhibitory activity of BBR against the replication of HCMV (strain not specified) was
921 previously reported (Hayashi et al., 2007); however, the mechanism by which BBR impaired
922 HCMV replication was not defined. In the present study, we have demonstrated that BBR is a
923 broad-spectrum inhibitor of HCMV replication, including strains resistant to drugs that target viral
924 DNA polymerase, thus suggesting that its mechanism of action differs from that of the currently
925 used DNA polymerase inhibitors. To support further this hypothesis, we showed that BBR
926 selectively reduced the expression of representative E and L viral proteins, without affecting that of
927 IE proteins, and inhibited the synthesis of viral DNA as well, thus suggesting that these inhibitory
928 effects of BBR most likely account for its marked overall antiviral activity on HCMV replication.
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944

945
946
947 Based on these facts, we hypothesized that BBR could target a molecular event involved in the
948
949 switch from IE to E phase of virus replication cycle. Indeed, BBR strongly reduced the ability of
950
951 IE2 to transactivate two different versions of a prototypic E gene promoter, i.e., the *UL54* gene
952
953 promoter. Although other molecular mechanisms cannot be totally ruled out, the effect of BBR
954
955 seems to be specific for the IE2 transactivating activity, since we observed that: i) it inhibited the
956
957 activation of gene promoters of both viral and cellular origin that depend on IE2 for their
958
959 transcriptional activity (Fig. 4); ii) it did not significantly affect neither the transcriptional activity
960
961 of viral gene promoters responsive to general cellular transcription factors, nor the Tat-dependent
962
963 transactivation of HIV-1 LTR (Fig. 5); and iii) it did not exert any interference with the
964
965 transactivating activity of the closely related IE1 protein (Fig. 5), which shares 85 N-terminal
966
967 residues with IE2 (Stinski and Petrik, 2008).
968
969

970
971 Among molecules targeting IE2, BBR acts differently from fomivirsen, the only IE2
972
973 inhibitor that had been approved for the treatment of HCMV infections so far (Britt and Prichard,
974
975 2018), since unlike the latter it does not inhibit the expression of IE2 (Fig. 3). BBR in fact interferes
976
977 with the transactivating properties of IE2 (Fig. 4), and therefore, along with NTZ (Mercorelli et al.,
978
979 2016), it belongs to a novel class of anti-HCMV agents that can act by interfering with the
980
981 transactivating activity of IE2.
982

983
984 It is known that BBR can modulate multiple host cell signaling pathways, including NF- κ B (Pandey
985
986 et al., 2008) and mitogen activated protein kinases (MAPK) (Cui et al., 2009). Since these pathways
987
988 are also activated by HCMV infection and contribute to the efficient viral gene expression and
989
990 progression of HCMV replicative cycle (Johnson et al., 2000; DeMeritt et al., 2004; Caposio et al.,
991
992 2007; Caposio et al., 2010), it is possible that BBR may hinder the full activation of these
993
994 transduction pathways in HCMV-infected cells, thus leading to a significant impairment of viral
995
996 replication. In this regard, Song *et al.* observed that BBR inhibits HSV IE protein expression when
997
998 added on cells *before* HSV infection (Song et al., 2014). This inhibition was associated to an
999
1000 impairment of HSV-induced NF- κ B activation, indicating that BBR compromises a very early stage
1001
1002
1003

1004
1005
1006 of the HSV replication cycle, such as the IE gene expression. The NF- κ B pathway is activated very
1007
1008 early also by HCMV infection and is required to kick-start the viral IE gene expression (Caposio et
1009
1010 al., 2007). However, it is unlikely that BBR could affect NF- κ B activation in HCMV-infected cells,
1011
1012 since we did not observe any significant effect on the accumulation of IE proteins (Fig. 3), whose
1013
1014 expression is driven by the Major IE Promoter (MIEP) of HCMV that contains four NF- κ B sites
1015
1016 (Stinski and Meier, 2007). Moreover, in different virus models, such as those of influenza and Zika
1017
1018 viruses, it has been observed that BBR affects virus replication after the initial attachment and entry
1019
1020 (Cecil et al., 2011; Robinson et al., 2018).
1021
1022

1023
1024 BBR is also a known inhibitor of MAPKs pathway, in particular ERK1/2 and p38 kinases (Cui et
1025
1026 al., 2009; Shin et al., 2015; Varghese et al., 2016b). Relevant to this activity of BBR, it is well
1027
1028 established that HCMV activates several MAPKs, including ERK1/2 and p38 (Johnson et al., 2000;
1029
1030 Caposio et al., 2010), and that an appropriate phosphorylation of MAPKs downstream partners in
1031
1032 HCMV-infected cells is required for efficient progression of the viral replicative cycle (Johnson et
1033
1034 al., 2001). Given that IE2 can be phosphorylated by MAPKs *in vitro* (Harel and Alwine, 1998), and
1035
1036 the phosphorylation status modulates IE2-dependent transcriptional activation of gene promoters
1037
1038 (Barrasa et al., 2005), one could hypothesize that the inhibitory activity of BBR on the IE2-
1039
1040 dependent transactivation of E genes may descend from its ability to hamper MAPKs activation.
1041
1042 Noteworthy, the block of MAPKs pathway was recently identified as the mechanism of the antiviral
1043
1044 activity of BBR against RSV and alphaviruses (Shin et al., 2015; Varghese et al., 2016b). Relevant
1045
1046 to the above hypothesis, it is worth mentioning that the p38 kinase inhibitor FHPI was reported to
1047
1048 halt HCMV replicative cycle after IE gene expression and prior to the onset of viral DNA
1049
1050 replication (Johnson et al., 1999), thus in the same time frame of the HCMV replication cycle that
1051
1052 we identified as the main target of the antiviral activity of BBR (Fig. 3). Clearly, further
1053
1054 experimentation is required to confirm this hypothesis and it will be object of future studies.
1055
1056

1057
1058 BBR is active against a broad range of different microbial pathogens (Kumar et al., 2015), thus it
1059
1060 may offer advantages over other current anti-HCMV drugs, since HCMV infection can increase the
1061
1062

1063
1064
1065 risk in immunosuppressed patients of other opportunistic infections, such as bacterial and fungal
1066
1067 infections. Moreover, BBR shows very low toxicity and side effects (Pang et al., 2015) and these
1068
1069 features, together with the other pharmacological properties, point out BBR as an interesting
1070
1071 candidate to develop alternative anti-HCMV therapeutic strategies.
1072
1073

1074 1075 1076 **5. Conclusion**

1077
1078 In conclusion, the results of this study suggest BBR as another attractive candidate for a new
1079
1080 class of anti-HCMV drugs that exert their effects via novel pathways that target IE2 functions, and
1081
1082 warrant further investigations to evaluate whether BBR may be effective in animal models of CMV
1083
1084 infection. Indeed, BBR is active also against MCMV replication and prevents the transactivation of
1085
1086 a prototypic MCMV E gene mediated by the IE3 protein, the murine homolog of HCMV IE2.
1087
1088 Given this high similarity between HCMV IE2 and MCMV IE3, the investigation of the therapeutic
1089
1090 potential of BBR in the murine model of CMV infection is worth pursuing.
1091
1092
1093
1094

1095 **Funding**

1096
1097 This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, grant n.
1098
1099 IG18855) to A. Loregian; by the University of Padua (Progetto di Ricerca di Ateneo 2014, grant no.
1100
1101 PDA141311) to A. Loregian, by FINDER STARS Consolidator Grant to B.M., and by the
1102
1103 University of Torino (Ricerca Locale) to A. Luganini and G.G. Funding sources had no role in
1104
1105 experimental design, data collection, data interpretation or the decision to submit the work for
1106
1107 publication.
1108
1109
1110
1111

1112 **Declaration of interest**

1113
1114 All authors declare no conflicts of interest.
1115
1116
1117

1118 **Acknowledgments**

1119
1120
1121

1122
1123
1124 We thank C. Sinzger (University of Ulm, Germany) for HCMV TB40-UL32-EGFP, and G. Gerna
1125
1126 (IRCCS Policlinico San Matteo, Pavia, Italy) for HCMV VR1814. We are grateful to E.A.
1127
1128 Thompson, S. Richter, and A. Caputo for providing plasmids used in this study.
1129
1130
1131
1132

1133 **References**

1134
1135 Barrasa, M.I., Harel, N.Y., Alwine, J.C., 2005. The phosphorylation status of the serine-rich region
1136 of the human cytomegalovirus 86-kilodalton major immediate-early protein IE2/IEP86 affects
1137 temporal viral gene expression. *J. Virol.* 79, 1428-1437.
1138

1139 Beelontally, R., Wilkie, G.S., Lau, B., Goodmaker, C.J., Ho, C.M.K., Swanson, C.M., Deng, X.,
1140 Wang, J., Gray, N.S., Davison, A.J., Strang, B.L., 2017. Identification of compounds with anti-
1141 human cytomegalovirus activity that inhibit production of IE2 proteins. *Antivir. Res.* 138, 61-67.
1142

1143 Bray, M., Andrei, G., Ballana, E., Carter, K., Durantel, D., Gentry, B., Janeba, Z., Moffat, J.,
1144 Oomen, C.J., Tarbet, B., Riveira-Munoz, E., Este, J.A., International Society for Antiviral Research
1145 2018. Meeting report: 31st International Conference on Antiviral Research. *Antivir. Res.* 158, 88-
1146 102.
1147

1148
1149 Bresnahan, W.A., Albrecht, T., Thompson, E.A., 1998. The cyclin E promoter is activated by
1150 human cytomegalovirus 86-kDa immediate early protein. *J. Biol. Chem.* 273:22075-22082.
1151

1152 Britt, W.J., 2018. Maternal immunity and the natural history of congenital human cytomegalovirus
1153 infection. *Viruses* 10, pii: E405.
1154

1155 Britt, W.J., and Prichard, M.N., 2018. New therapies for human cytomegalovirus infections.
1156 *Antivir. Res.* 159:153-174.
1157

1158 Caposio, P., Luganini, A., Hahn, G., Landolfo, S., Gribaudo, G., 2007. Activation of the virus-
1159 induced IKK/NF-kappaB signalling axis is critical for the replication of human cytomegalovirus in
1160 quiescent cells. *Cell. Microbiol.* 9, 2040-2054.
1161

1162 Caposio, P., Luganini, A., Bronzini, M., Landolfo, S., Gribaudo, G. 2010. The Elk-1 and Serum
1163 Response Factor binding sites in the Major Immediate-Early promoter of human cytomegalovirus
1164 are required for efficient viral replication in quiescent cells and compensate for inactivation of the
1165 NF-κB sites in proliferating cells. *J. Virol.*, 84, 4481-4493.
1166
1167

1168 Cavaletto, N., Luganini, A., Gribaudo, G. 2015. Inactivation of the human cytomegalovirus US20
1169 gene hampers productive viral replication in endothelial Cells. *J. Virol.* 89, 11092–11106.
1170

1171 Cecil, C.E., Davis, J.M., Cech, N.B., Laster, S.M., 2011. Inhibition of H1N1 influenza A virus
1172 growth and induction of inflammatory mediators by the isoquinoline alkaloid berberine and extracts
1173 of goldenseal (*Hydrastis canadensis*). *Int. Immunopharmacol.* 11, 1706-1714.
1174

1175 Cui, G., Qin, X., Zhang, Y., Gong, Z., Ge, B., Zang, Y.Q., 2009. Berberine differentially modulates
1176 the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type
1177 1 diabetic mice. *J. Biol. Chem.* 284, 28420-28429.
1178
1179
1180

1181
1182
1183
1184 DeMeritt, I.B., Milford, L.E., Yurochko, A.D., 2004. Activation of the NF-kappaB pathway in
1185 human cytomegalovirus-infected cells is necessary for efficient transactivation of the major
1186 immediate-early promoter. *J. Virol.* 78, 4498-4507.
1187

1188
1189 Gardner, T.J., Cohen, T., Redmann, V., Lau, Z., Felsenfeld, D., Tortorella, D., 2015. Development
1190 of a high-content screen for the identification of inhibitors directed against the early steps of the
1191 cytomegalovirus infectious cycle. *Antivir. Res.* 113, 49-61.
1192

1193 Gariano, G.R., Dell'Oste, V., Bronzini, M., Gatti, D., Luganini, A., Andrea, M.D., Gribaudo, G.,
1194 Gariglio, M., Landolfo, S., 2012. The intracellular DNA sensor IFI16 gene acts as restriction factor
1195 for human cytomegalovirus replication. *PLoS Pathog.* 8, e1002498.
1196

1197 Gibellini, D., Caputo, A., Celeghini, C., Bassini, A., La Placa, M., Capitani, S., Zauli, G., 1995. Tat-
1198 expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute
1199 human immunodeficiency virus-type 1 (HIV-1) infection. *Br. J. Haematol.* 89, 24-33.
1200

1201 Gribaudo, G., Riera, L., Rudge, T.L., Caposio, P., Johnson, L.F., Landolfo, S., 2002. Human
1202 cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent
1203 fibroblasts. *J. Gen. Virol.* 83, 2983-2993.
1204

1205 Griffiths, P., Baraniak, I., Reeves, M., 2015. The pathogenesis of human cytomegalovirus. *J. Pathol.*
1206 235, 288-297.
1207

1208 Haidar, G., Singh, N., 2017. Viral infections in solid organ transplant recipients: novel updates and
1209 a review of the classics. *Curr. Opin. Infect. Dis.* 30, 579-588.
1210

1211 Harel, N.Y., Alwine, J.C., 1998. Phosphorylation of the human cytomegalovirus 86-kilodalton
1212 immediate-early protein IE2. *J. Virol.* 72, 5481-5492.
1213

1214 Hayashi, K., Minoda, K., Nagaoka, Y., Hayashi, T., Uesato, S., 2007. Antiviral activity of berberine
1215 and related compounds against human cytomegalovirus. *Bioorg. Med. Chem. Lett.* 17, 1562-1564.
1216

1217 Imenshahidi, M., Hosseinzadeh, H., 2016. *Berberis vulgaris* and berberine: An update review.
1218 *Phytother. Res.* 30, 1745-1764.
1219

1220 Johnson, R.A., Huong, S.M., Huang, E.S., 1999. Inhibitory effect of 4-(4-fluorophenyl)-2-(4-
1221 hydroxyphenyl)-5-(4-pyridyl)1H-imidazole on HCMV DNA replication and permissive infection.
1222 *Antiv. Res.* 41, 101-111.
1223

1224 Johnson, R.A., Huong, S.M., Huang, E.S., 2000. Activation of the mitogen-activated protein kinase
1225 p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for
1226 activation of p38. *J. Virol.* 74, 1158-1167.
1227

1228 Johnson, R.A., Ma, X.L., Yurochko, A.D., Huang, E.S., 2001. The role of MKK1/2 kinase activity
1229 in human cytomegalovirus infection. *J. Gen. Virol.* 82, 493-497.
1230

1231 Kerry, J.A., Priddy, M.A., Jerve, T.Y., Kohler, C.P., Staley, T.L., Vanson, C.D., Jones, T.R.,
1232 Iskenderian, A.C., Anders, D.G., Stenberg, R.M. 1996. Multiple regulatory events influence human
1233 cytomegalovirus DNA polymerase (UL54) expression during viral infection. *J. Virol.* 70, 373-382.
1234
1235
1236
1237
1238
1239

- 1240
1241
1242 Klucher, K.M., Sommer, M., Kadonaga, J.T., Spector, D.H., 1993. In vivo and in vitro analysis of
1243 transcriptional activation mediated by the human cytomegalovirus major immediate-early proteins.
1244 Mol. Cell. Biol. 13, 1238-1250.
1245
- 1246 Kumar, A., Ekavali, Chopra, K., Mukherjee, M., Pottabathini, R., Dhull, D.K., 2015. Current
1247 knowledge and pharmacological profile of berberine: An update. Eur. J. Pharmacol. 761, 288-297.
1248
1249
- 1250 Loregian, A., Coen, D.M., 2006. Selective anti-cytomegalovirus compounds discovered by
1251 screening for inhibitors of subunit interactions of the viral polymerase. Chem. Biol.13, 191-200.
1252
- 1253 Loregian, A., Mercorelli, B., Muratore, G., Sinigalia, E., Pagni, S., Massari, S., Gribaudo, G., Gatto,
1254 B., Palumbo, M., Tabarrini, O., Cecchetti, V., Palù, G., 2010. The 6-aminoquinolone WC5 inhibits
1255 human cytomegalovirus replication at an early stage by interfering with the transactivating activity
1256 of viral immediate-early 2 protein. Antimicrob. Agents Chemother. 54, 1930-1940.
1257
- 1258 Luganini, A., Caposio, P., Mondini, M., Landolfo, S., Gribaudo, G., 2008. New cell-based indicator
1259 assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral
1260 immediate-early 2 protein activity. J. Appl. Microbiol. 105, 1791-1801.
1261
- 1262 Luganini, A., Terlizzi, M.E., Gribaudo, G., 2016. Bioactive molecules released from cells infected
1263 with the human cytomegalovirus. Front. Microbiol. 7:715.
1264
- 1265 Martinez, F.P., Cosme, R.S.C., Tang, Q., 2010. Murine cytomegalovirus major immediate-early
1266 protein 3 interacts with cellular and viral proteins in viral DNA replication compartments and is
1267 important for early gene activation. J. Gen. Virol. 91, 2664-2676.
1268
1269
- 1270 Marty, F.M., Ljungman, P., Chemaly, R.F., Maertens, J., Dadwal, S.S., Duarte, R.F., Haider, S.,
1271 Ullmann, A.J., Katayama, Y., Brown, J., Mullane, K.M., Boeckh, M., Blumberg, E.A., Einsele, H.,
1272 Snyderman, D.R., Kanda, Y., DiNubile, M.J., Teal, V.L., Wan, H., Murata, Y., Kartsonis, N.A.,
1273 Leavitt, R.Y., Badshah, C., 2017. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell
1274 transplantation. N. Engl. J. Med. 377, 2433-2444.
1275
- 1276 Meesing, A., Razonable, R.R., 2018. New developments in the management of cytomegalovirus
1277 infection after transplantation. Drugs 78, 1085-1103.
1278
- 1279 Mercorelli, B., Gribaudo, G., Palu`, G., and Loregian, A. 2014a. Approaches for the generation of
1280 new anti-cytomegalovirus agents: identification of protein protein interaction inhibitors and
1281 compounds against the HCMV IE2 protein. Methods Mol. Biol. 1119, 349-363.
1282
- 1283 Mercorelli, B., Lembo, D., Palu, G., Loregian, A., 2011. Early inhibitors of human
1284 cytomegalovirus: state-of-art and therapeutic perspectives. Pharmacol. Ther. 131, 309-329.
1285
1286
- 1287 Mercorelli, B., Luganini, A., Celegato, M., Palù, G., Gribaudo, G., Loregian, A., 2018a.
1288 Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early
1289 inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein. Antivir. Res.
1290 150, 130-136.
1291
- 1292 Mercorelli, B., Luganini, A., Muratore, G., Massari, S., Terlizzi, M.E., Tabarrini, O., Gribaudo, G.,
1293 Palù, G., Loregian, A., 2014b. The 6-Aminoquinolone WC5 inhibits different functions of the
1294 immediate-early 2 (IE2) protein of human cytomegalovirus that are essential for viral replication.
1295 Antimicrob. Agents Chemother. 58, 6615-6626.
1296
1297
1298

1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357

Mercorelli, B., Luganini, A., Nannetti, G., Tabarrini, O., Palù, G., Gribaudo, G., Loregian, A., 2016. Drug repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication. *Cell Chem. Biol.* 23, 340-351.

Mercorelli, B., Muratore, G., Sinigalia, E., Tabarrini, O., Biasolo, M.A., Cecchetti, V., Palù, G., Loregian, A., 2009. A 6-aminoquinolone compound, WC5, with potent and selective anti-human cytomegalovirus activity. *Antimicrob. Agents Chemother.* 53, 312-315.

Mercorelli, B., Palù, G., Loregian, A., 2018b. Drug repurposing for viral infectious diseases: How far are we? *Trends Microbiol.* 26, 865-876.

Messerle, M., Buhler, B., Keil, G.M., Koszinowski, U.H., 1992. Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3. *J. Virol.* 66, 27-36.

Ne, E., Palstra, R.J., Mahmoudi, T., 2018. Transcription: Insights from the HIV-1 promoter. *Int. Rev. Cell. Mol. Biol.* 335, 191-243.

Pandey, M.K., Sung, B., Kunnumakkara, A.B., Sethi, G., Chaturvedi, M.M., Aggarwal, B.B., 2008. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. *Cancer Res.* 68, 5370-5379.

Pang, B., Zhao, L.-H., Zhou, Q., Zhao, T.-Y., Wang, H., Gu, C.-J., Tong, X.-L., 2015. Application of berberine on treating type 2 diabetes mellitus. *Int. J. Endocrinol.* 2015, 905749.

Perrone, R., Nadai, M., Frasson, I., Poe, J.A., Butovskaya, E., Smithgall, T.E., Palumbo, M., Palù, G., Richter, S.N., 2013. A dynamic G-quadruplex region regulates the HIV-1 long terminal repeat promoter. *J. Med. Chem.* 56, 6521-6530.

Razonable, R.R., 2018. Drug-resistant cytomegalovirus: clinical implications of specific mutations. *Curr. Opin. Organ. Transplant.* 23, 388-394.

Revello, M.G., Lilleri, D., Zavattoni, M., Stronati, M., Bollani, L., Middeldorp, J.M., Gerna, G., 2001. Human cytomegalovirus immediate-early messenger RNA in blood of pregnant women with primary infection and of congenitally infected newborns. *J. Infect. Dis.* 184, 1078-1081.

Robinson, C.L., Chong, A.C.N., Ashbrook, A.W., Jeng, G., Jin, J., Chen, H., Tang, E.I., Martin, L.A., Kim, R.S., Kenyon, R.M., Do, E., Luna, J.M., Saeed, M., Zeltser, L., Ralph, H., Dudley, V.L., Goldstein, M., Rice, C.M., Cheng, C.Y., Seandel, M., Chen, S., 2018. Male germ cells support long-term propagation of Zika virus. *Nat. Commun.* 9, 2090.

Sampaio, K.L., Cavignac, Y., Stierhof, Y.D., Sinzger, C., 2005. Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. *J. Virol.* 79, 2754-2767.

Scholz, M., Doerr, H.W., Cinatl, J., 2001. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? *Antivir. Res.* 49, 129-145.

1358
1359
1360 Shin, H.-B., Choi, M.-S., Yi, C.-M., Lee, J., Kim, N.-J., Inn, K.-S., 2015. Inhibition of respiratory
1361 syncytial virus replication and virus-induced p38 kinase activity by berberine. *Int.*
1362 *Immunopharmacol.* 27, 65-68.
1363

1364 Song, S., Qiu, M., Chu, Y., Chen, D., Wang, X., Su, A., Wu, Z., 2014. Downregulation of cellular
1365 c-Jun N-terminal protein kinase and NF-kappaB activation by berberine may result in inhibition of
1366 herpes simplex virus replication. *Antimicrob. Agents Chemother.* 58, 5068-5078.
1367
1368

1369 Stinski, M.F., Meier, J.L., 2007. Immediate-early viral gene regulation and function, in: Arvin, A.,
1370 Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K. (Eds.),
1371 *Human herpesviruses: biology, therapy, and immunoprophylaxis.* Cambridge: Cambridge
1372 University Press; Chapter 17.
1373

1374 Stinski, M.F., Petrik, D.T., 2008. Functional roles of the human cytomegalovirus essential IE86
1375 protein. *Curr. Top. Microbiol. Immunol.* 325, 133-152.
1376

1377 Varghese, F.S., Kaukinen, P., Glasker, S., Bepalov, M., Hanski, L., Wennerberg, K., Kummerer,
1378 B.M., Ahola, T., 2016a. Discovery of berberine, abamectin and ivermectin as antivirals against
1379 chikungunya and other alphaviruses. *Antivir. Res.* 126, 117-124.
1380

1381 Varghese, F.S., Thaa, B., Amrun, S.N., Simarmata, D., Rausalu, K., Nyman, T.A., Merits, A.,
1382 McInerney, G.M., Ng, L.F.P., Ahola, T., 2016b. The Antiviral Alkaloid Berberine Reduces
1383 Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling. *J. Virol.* 90, 9743-9757.
1384
1385

1386 Wang, H., Li, K., Ma, L., Wu, S., Hu, J., Yan, H., Jiang, J., Li, Y., 2017. Berberine inhibits
1387 enterovirus 71 replication by downregulating the MEK/ERK signaling pathway and autophagy.
1388 *Virol. J.* 14, 2.
1389
1390

1391 **Figure legends**

1392

1393 **Figure 1. BBR exerts a dose-dependent inhibition of HCMV AD169 replication.** HFFs were
1394 infected with HCMV AD169 and then treated with different concentrations of BBR (from 0.01 to
1395 100 μ M), and incubated at 37°C for 10 days. Data shown are expressed as a percentage of the
1396 plaque number determined in treated samples with respect to the DMSO-treated and mock-infected
1397 controls and represent the means \pm SD of three independent experiments performed in duplicate.
1398
1399

1400 **Figure 2. Berberine inhibits viral DNA synthesis in HCMV-infected cells.** Infected HFFs were
1401 treated with 50 μ M BBR, 25 μ M GCV, or 0.1% DMSO as a control. At 24, 72, 96, and 120 h p.i.,
1402 total DNA was extracted and qPCR was performed with appropriate *IE2* and *β -globin* primers.
1403
1404

1405 HCMV genomic copies were normalized to the cellular *β -globin* copies. Data shown are the means
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416

1417
1418
1419 \pm SD of four independent experiments performed in duplicate. * $p < 0.05$; ** $p < 0.01$ versus
1420
1421 calibrator sample (DMSO).
1422

1423 **Figure 3. Berberine reduces the expression of E and L HCMV proteins.** HFFs were mock-
1424
1425 infected or infected with AD169 (MOI of 0.5 PFU/cell) and after 2 h of viral adsorption, cells were
1426
1427 treated with 50 μ M BBR, 30 μ M NTZ, or with 0.1% DMSO (added in mock-infected and virus-
1428
1429 infected samples). Total cell protein extracts were prepared at the indicated times p.i., fractionated
1430
1431 by SDS-PAGE, and analyzed by immunoblotting. Protein markers sizes are indicated in kilodaltons.
1432
1433

1434 **Figure 4. BBR inhibits the IE2-dependent transactivation of viral and cellular promoters.** (A)

1435 HELF cells were transfected with the luciferase reporter plasmids pUL54-0.4 or pUL54-0.15.
1436
1437

1438 Twenty-four hours later, transfected cells were transduced with AdvIE2 or AdvLacZ at a MOI of
1439
1440 20 PFU/cell and then treated with 50 μ M BBR, 30 μ M NTZ, 5 μ M ISIS 2922, or 0.1% DMSO.
1441

1442 Luciferase reporter activity was measured 48 h later to determine promoter activation under the
1443
1444 different conditions. Data represent the means \pm SD from three independent experiments in
1445
1446 triplicate. The results were analyzed by one-way ANOVA with Bonferroni post-test correction for
1447
1448 multiple comparisons. *** $p < 0.0001$; versus calibrator sample (AdvIE2 + DMSO).
1449

1450 (B) (C) U373-MG cells were transfected with either (B) pCycE wt or (C) mutated mpCycE
1451
1452 indicator constructs along with either the empty pSG5 plasmid or the IE2-expressing pSGIE86
1453
1454 (IE2) plasmid and treated for 48 h with 25 or 50 μ M BBR, or 0.1% DMSO as a control. Then,
1455
1456 activation of CycE promoters under the different conditions was determined. Data represent the
1457
1458 means \pm SD from four independent experiments in duplicate. The results were analyzed by one-way
1459
1460 ANOVA with Bonferroni post-test correction for multiple comparisons. ** $p < 0.005$; * $p < 0.05$;
1461
1462 versus calibrator sample (pCycE or mpCycE + DMSO).
1463
1464
1465

1466 **Figure 5. BBR is not a general inhibitor of transcription.** U373-MG cells were transfected with
1467
1468 either (A) HCMV MIEP or (B) HIV-1 LTR indicator constructs along with either the empty pSG5
1469
1470 plasmid or a Tat-expressing plasmid and treated for 48 h with 25 or 50 μ M BBR, or 0.1% DMSO as
1471
1472 a control. Then, promoter activation under the different conditions was determined. Data represent
1473
1474
1475

1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534

the means \pm SD from four independent experiments in duplicate. The results were analyzed by one-way ANOVA with Bonferroni post-test correction for multiple comparisons versus the calibrator sample (pMIEP + DMSO for panel A; LTR + DMSO or LTR + Tat + DMSO for panel B).

(C) HELF cells were co-transfected with phTS-243/+30 reporter vector along with empty pSG5 vector or an IE1-expressing vector. At 18 h after transfection, cells were washed and treated with 50 μ M BBR, 30 μ M NTZ, or 0.1% DMSO (v/v) for 48 h. Then, phTS promoter activation under the different conditions was determined. The data shown are the mean \pm SD of two experiments, each performed in triplicate. Data were analyzed by an unpaired t-test. **p <0.001; versus calibrator sample (phTS-243/+30 + pIE1 + DMSO).

Figure 6. BBR abrogates the IE3-dependent transactivation of the Early *E1* gene promoter of MCMV. NIH3T3 cells were transfected with a plasmid containing luciferase reporter gene under the control of the *E1* promoter (pGL3-E1) or co-transfected with an IE3-expressing plasmid (pIE3) and then treated with 50 μ M BBR, 50 μ M WC5, or 0.1% DMSO. After 48 h, *E1* promoter activation under the different conditions was determined. Data shown are the means \pm SD from two independent experiments in triplicate and were analyzed by an unpaired t-test. *p < 0.01; **p < 0.001; versus calibrator sample (pGL3-E1 + pIE3 + DMSO).

Table 1. Antiviral activity of BBR against HCMV AD169.

Compound	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
BBR	2.65 ± 0.35	390 ± 10	147
GCV	2.5 ± 0.5	>500	>200

^a50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs against HCMV AD169 in HFF cells. Reported values represent the means ± the SD of data derived from three independent experiments in triplicate.

^b50% Cytotoxic Concentration, the compound concentration that results in 50% of cytotoxicity, as determined by MTT assays in HFF cells. Reported values represent the means ± the SD of data derived from at least three independent experiments performed in quadruplicate.

^cSI, Selectivity Index (determined as CC₅₀/EC₅₀).

Table 2. Activity of BBR against different HCMV strains.

HCMV Strain	BBR EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
TB40-UL32-EGFP	2.70 ± 1.13	390 ± 10	144
VR1814	4.00 ± 0.71	390 ± 10	98
388438U	1.30 ± 0.42	390 ± 10	300

^a50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs in HFF cells. Reported values represent the means ± the SD of data derived from at least three independent experiments in triplicate.

^b50% Cytotoxic Concentration, the compound concentration that results in 50% of cytotoxicity, as determined by MTT assays in HFF cells. Reported values represent the means ± the SD of data derived from at least three independent experiments performed in quadruplicate.

^cSI, Selectivity Index (determined as CC₅₀/EC₅₀).

Table 3. Comparison of the activity of BBR against AD169 and drug-resistant HCMV strains.

HCMV Strain	Drug resistance	BBR EC ₅₀ ^a (μM)	Control ^b EC ₅₀ (μM)
AD169	None	2.35 ± 0.35	N.D.
GDG ^r P53	GCV, CDV	1.45 ± 0.08	75 ± 5
PFA ^r D100	FOS, ACV	1.40 ± 0.57	305 ± 18

^a50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs in HFF cells. Reported values represent the means ± the SD of data derived from at least three independent experiments in triplicate.

^bGCV was used for GDG^rP53 and FOS for PFA^rD100.

N.D., not determined.


Table 4. Antiviral activity of BBR against MCMV.


Compound	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
BBR	1.95 ± 0.35	192 ± 12	98
CDV	0.53 ± 0.18	> 250	>472


^a50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs against MCMV Smith in NIH 3T3 cells. Reported values represent the means ± the SD of data derived from three independent experiments in triplicate.




^b50% Cytotoxic Concentration, the compound concentration that results in 50% of cytotoxicity, as determined by MTT assays in NIH 3T3 cells. Reported values represent the means ± the SD of data derived from at least three independent experiments performed in quadruplicate.



^cSI, Selectivity Index (determined as CC₅₀/EC₅₀).









A**B****C**